NaV1.8 gene-silencing siRNAs (Alnylam)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameNaV1.8 gene-silencing siRNAs (Alnylam)
Drug Alias Namevoltage-gated sodium channel 1.8 gene-silencing siRNAs (Alnylam)
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionSodium channel protein type X alpha subunit blockers
TargetsSodium channel protein type X alpha subunit
Therapy Area/IndicationsPain
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAlnylam Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAlnylam Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsPain

Other Information

ATC CodeN/A
Related LinksN/A